ContraFect and National Institute for Viral Disease Control and Prevention, China CDC Sign Agreement to Collaborate on Universal Influenza Treatment

Yonkers, NY, October 9, 2014 – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ:CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that they have entered into a collaborative research agreement with the National Institute for Viral Disease Control and Prevention, China CDC (“IVDC”) to advance research and development of CF-404, its Universal Influenza Treatment. “Working with the IVDC in China provides ContraFect access to some of the world’s top experts in the field of influenza,” stated Julia P. Gregory, ContraFect’s chief executive officer. “As new strains of influenza often arise in China, working with the Chinese agency allows us to test our Universal Influenza Therapy, CF-404, on the relevant strains of influenza by their expert team.” “The IVDC believes it is very important to address serious or life-threatening Influenza and looks forward to working with ContraFect’s new medicine to treat this global threat,” commented Yuelong Shu, deputy director of the IVDC.

This entry was posted in Recent Development News: Q4 – 2014. Bookmark the permalink.